Toth Financial Advisory Corp Neurocrine Biosciences Inc Transaction History

Toth Financial Advisory Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 16, 2024	BUY	$130.86 - $143.19 $23,554 - $25,774	180 Added 3.27%	5,680 $781,000
Q1 2024 Apr 16, 2024	BUY	$130.4 - $143.74 $184,255 - $203,104	1,413 Added 34.57%	5,500 $758,000
Q4 2023 Jan 26, 2024	BUY	$106.07 - $132.76 $433,508 - $542,590	4,087 New	4,087 $538,000
Q4 2022 Jan 24, 2023	BUY	$106.72 - $127.06 $766,783 - $912,926	7,185 New	7,185 $0
Q4 2020 Jan 25, 2021	SELL	$86.91 - $108.33 $42,585 - $53,081	-490 Closed	0 $0
Q3 2020 Oct 16, 2020	SELL	$96.16 - $135.15 $658,215 - $925,101	-6,845 Reduced 93.32%	490 $47,000
Q2 2020 Jul 14, 2020	BUY	$85.09 - $130.36 $521,601 - $799,106	6,130 Added 508.71%	7,335 $894,000
Q1 2020 Apr 20, 2020	SELL	$75.11 - $113.76 $326,728 - $494,856	-4,350 Reduced 78.31%	1,205 $104,000
Q4 2019 Jan 27, 2020	BUY	$86.8 - $118.57 $482,174 - $658,656	5,555 New	5,555 $597,000

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Toth Financial Advisory Corp, based on Form 13F filings with the SEC.

Stay updated on Toth Financial Advisory Corp with notifications on news.